ATXI - Watch this One After Reaching Final Agreement with the U.S. FDA for the Phase 3 Safety Study for IV Tramadol

2024-01-04 08:58:40 ET

DENVER, Colo., Jan. 4, 2024 ( www.247marketnews.com )- Avenue Therapeutics, Inc. (NASDAQ: ATXI) reported, this morning, that it reached final agreement with the U.S. Food and Drug Administration (“FDA”) on the Phase 3 safety study protocol and statistical analysis approach, including the primary endpoint, for intravenous (IV) tramadol, which is in development for the treatment of acute post-operative pain in a medically supervised setting, designed to assess the theoretical risk of opioid-induced respiratory depression related to opioid stacking on IV tramadol compared to IV morphine.

Avenue Therapeutics is trading at $0.2355, up $0.0595 (+33.81%), on 5.6M shares traded.

Its 52-week range is $0.1302 to $2.35. It hit a 52-week low in mid-December and this move should smash through a bunch …

The post Watch this One After Reaching Final Agreement with the U.S. FDA for the Phase 3 Safety Study for IV Tramadol appeared first on 24/7 Market News .

For further details see: